Ablynx NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Ablynx NV Elects New Chairman Of Board
Ablynx NV announced that it is the intention of the Board to separate the roles of Chairman and CEO. The Board intends to elect Dr Fellner as Chairman to succeed Dr Moses who will remain Chief Executive Officer. The Company also announced that it is the intention of Dr Stephen Bunting and Mr Denis Lucquin to resign from the Ablynx Board.
Latest Developments for Ablynx NV
- Ablynx NV's anti-Il-6r nanobody partnered with Abbvie demonstrates a bioavailability of more than 80 pct after subcutaneous injection
- Ablynx NV's Anti-vwf Nanobody, Caplacizumab, achieves clinical proof-of-concept in Phase II Titan study
- Ablynx to present additional positive data on anti-IL-6R Nanobody ALX-0061
- Ablynx NV issues pipeline update
Latest Key Developments in Biotechnology
- LBT Innovations Limited completes Australian clinical trials of APAS technology
- Amarantus announces positive preclinical data on the effects of MANF on Vision in model of retinitis pigmentosa
- Medgenics Inc prices public offering of common stock
- Eleven Biotherapeutics announces additional financing of $20 mln
- Share this
- Digg this